Gary Gordon Buys 10,000 Shares of TriSalus Life Sciences (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Gary Gordon purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average cost of $2.46 per share, with a total value of $24,600.00. Following the completion of the acquisition, the director directly owned 72,510 shares in the company, valued at approximately $178,374.60. This represents a 16.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

TriSalus Life Sciences Trading Up 4.0%

TLSI stock opened at $3.15 on Wednesday. The business has a fifty day moving average price of $4.11 and a 200 day moving average price of $5.10. TriSalus Life Sciences, Inc. has a fifty-two week low of $2.20 and a fifty-two week high of $7.95. The stock has a market capitalization of $193.13 million, a price-to-earnings ratio of -2.23 and a beta of 0.56. The company has a debt-to-equity ratio of 2.58, a current ratio of 5.78 and a quick ratio of 5.46.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The business had revenue of $13.21 million for the quarter, compared to analyst estimates of $13.20 million. Analysts expect that TriSalus Life Sciences, Inc. will post -0.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on TLSI shares. Lake Street Capital dropped their price target on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Weiss Ratings cut TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Canaccord Genuity Group dropped their price target on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a report on Friday, March 6th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $7.50.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TLSI. Goldman Sachs Group Inc. bought a new position in TriSalus Life Sciences in the 1st quarter valued at $187,000. Geode Capital Management LLC boosted its position in TriSalus Life Sciences by 107.4% in the 2nd quarter. Geode Capital Management LLC now owns 455,051 shares of the company’s stock valued at $2,480,000 after buying an additional 235,627 shares during the last quarter. JPMorgan Chase & Co. boosted its position in TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after buying an additional 7,519 shares during the last quarter. New York State Common Retirement Fund bought a new position in TriSalus Life Sciences in the 2nd quarter valued at $108,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in TriSalus Life Sciences in the 2nd quarter valued at $47,000. 2.58% of the stock is currently owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.